Published in

Oxford University Press, The Journal of Infectious Diseases, 5(199), p. 711-716, 2009

DOI: 10.1086/596558

Links

Tools

Export citation

Search in Google Scholar

A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults

Journal article published in 2009 by Ruth A. Karron, Karen Callahan, Catherine Luke, Bhagvanji Thumar, Josephine McAuliffe, Elizabeth Schappell, Tomy Joseph ORCID, Kathleen Coelingh, Hong Jin, George Kemble, Brian R. Murphy, Kanta Subbarao
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 107-TCID50 doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had ≥4-fold increases in hemagglutination-inhibition antibody, and 79% had ≥4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults.